Managing Device Complications After Prior Radiation Therapy

Radiation therapy can leave a long cardiovascular footprint. Patients treated for Hodgkin lymphoma, breast cancer, lung cancer, oesophageal malignancy, or mediastinal disease may later develop conduction abnormalities, cardiomyopathy, valvular disease, coronary disease, venous obstruction, or tissue fibrosis. Some eventually require a pacemaker, implantable cardioverter-defibrillator (ICD), cardiac resynchronisation device, or loop recorder.

For electrophysiology teams, the relevant history extends beyond the cancer diagnosis and treatment date. The radiation field, cumulative dose, treatment technique, implanted anatomy, current cardiac substrate, and previous central venous access can all affect device selection and procedural safety. A careful plan is especially important in Australia, where patients may move between a local hospital, a metropolitan tertiary centre, and oncology services in different health networks.

Why Prior Radiation Changes Device Risk

Radiation-associated injury may involve the myocardium, pericardium, valves, coronary arteries, conduction system, and great vessels. Fibrosis can appear years after treatment, so a patient with a normal electrocardiogram soon after cancer therapy may later present with sinus node dysfunction, atrioventricular block, bundle branch disease, or ventricular arrhythmia. The interval between exposure and implantation should therefore be treated as clinically relevant, but not as a reason to deny an indicated device.

The tissues used for a pocket and venous access may also be altered. Chest-wall fibrosis, thin skin, impaired microvascular supply, and previous surgery can increase the likelihood of wound breakdown, haematoma, erosion, and infection. Radiation near the subclavian or brachiocephalic veins may contribute to stenosis, while repeated ports and central lines can further limit access. A standard left-sided implant may be unsuitable even when it would normally be the simplest option.

The radiation history should include the treated cancer, side and location, approximate dose where available, fractionation, treatment year, chemotherapy, surgery, and the presence of an existing device during treatment. Oncology records or radiotherapy planning documents can clarify whether the anticipated generator position lies within, near, or outside the treatment field.

Pre-Implantation Assessment

A baseline assessment should combine symptoms, a 12-lead ECG, transthoracic echocardiography, and review of prior imaging. Echocardiography can identify left ventricular dysfunction, restrictive physiology, valve disease, pulmonary hypertension, pericardial disease, and regional abnormalities. If coronary or structural disease is suspected, CT, cardiac MRI, stress imaging, or invasive assessment may be appropriate, provided the selected test is compatible with the proposed device pathway.

Venous mapping becomes particularly useful when there has been mediastinal radiation, prior ports, dialysis access, or previous cardiac hardware. Ultrasound, venography, and CT venography can help identify occlusion or collateralisation before the procedure. In patients with a complex history, early input from cardiac electrophysiology, oncology, imaging, vascular surgery, and cardiothoracic surgery may prevent an avoidable failed implant.

The arrhythmic indication should remain separate from assumptions about radiation exposure. A patient with atrial fibrillation may need anticoagulation and rhythm assessment, while another with advanced conduction disease may require pacing. For a broader discussion of interacting structural and rhythm considerations, clinicians may also consult this review of atrial fibrillation and PFO, particularly when embolic risk and competing cardiac findings complicate decision-making.

Choosing The Implant Site And System

The preferred pocket may be opposite the irradiated field, away from mastectomy or reconstructive surgery, or in a position with healthier soft tissue. Prepectoral placement is familiar and generally less invasive, but a subpectoral or alternative approach may be considered when skin coverage is poor or erosion risk is high. The choice should account for body habitus, prior breast treatment, cosmetic and functional concerns, future radiotherapy, and the likelihood of later lead revision.

Venous obstruction can require a contralateral approach, tunnelling, extraction-assisted access, femoral or iliac systems, or a leadless pacemaker. Leadless pacing can be attractive in selected patients with limited upper-body venous access or a high pocket-infection risk, although it does not provide every pacing mode and is not a universal substitute for a transvenous system. Subcutaneous ICDs may avoid intravascular leads, but their suitability depends on pacing needs, sensing, defibrillation testing, anatomy, and the nature of the ventricular arrhythmia.

A multidisciplinary decision is particularly valuable when a patient may need both bradycardia support and future defibrillation. A system that solves today’s access problem but creates difficulties for magnetic resonance imaging, radiotherapy planning, extraction, or future upgrades may carry a hidden cost.

Procedural And Early Postoperative Complications

Fibrotic tissue can make dissection more difficult and reduce haemostasis. Pocket haematoma, prolonged drainage, wound separation, infection, lead dislodgement, and pneumothorax should be anticipated rather than treated as unexpected events. Meticulous antibiotic practice, careful anticoagulation management, ultrasound-guided venous access, and a clear plan for haematoma prevention are important.

The skin deserves close attention after implantation. A pocket placed beneath irradiated or surgically compromised tissue may look satisfactory at discharge but deteriorate during healing. Early review should assess pain, erythema, swelling, drainage, skin colour, and threatened erosion. Fever or subtle wound change warrants prompt evaluation because device infection can progress along the lead system and often requires complete hardware removal.

Australian services vary in how quickly patients can access specialist review. Someone living in regional New South Wales, Queensland, Western Australia, or the Northern Territory may face long travel to a device clinic. Discharge planning should therefore include a local GP, a reachable electrophysiology service, wound-care instructions, and a defined pathway for urgent review rather than relying on a routine metropolitan appointment.

Lead Performance And Device Follow-Up

Radiation may affect the biological environment around leads more consistently than it affects the electronics themselves. Fibrosis, venous narrowing, altered tissue contact, and progressive cardiomyopathy can produce changes in pacing thresholds, sensing, impedance, or defibrillation performance. Lead noise and intermittent capture failure require differentiation from connector problems, insulation damage, myopotential oversensing, and electromagnetic interference.

Remote monitoring can detect alerts before symptoms emerge, including non-sustained ventricular tachycardia, atrial arrhythmia burden, lead impedance shifts, battery depletion, and loss of capture. However, a monitoring programme must be practical for the patient and the treating network. Poor mobile coverage in parts of the bush, changing accommodation, limited digital access, and fragmented records can weaken an otherwise sound surveillance plan.

Follow-up should include device interrogation, ECG review, echocardiography when clinically indicated, medication assessment, and periodic evaluation for heart failure or radiation-associated valve disease. Patients should understand the warning signs of infection, syncope, palpitations, inappropriate shocks, and pocket erosion. Clear documentation is also important when a person transfers between public and private care.

Radiotherapy In Patients With Existing Devices

When radiotherapy is required after implantation, the device should be identified early in the oncology pathway. The treatment team needs the manufacturer, model, lead configuration, pacing dependence, programmed settings, and recent interrogation report. The generator should be kept outside the radiation field whenever reasonably possible, with shielding and beam arrangements discussed by radiation oncology and medical physics.

Ionising radiation can cause transient or permanent device malfunction, with risk influenced by dose, beam energy, neutron production, distance, device type, and cumulative exposure. ICD patients require particular planning because inappropriate detection or therapy may occur. Depending on risk, the device may need reprogramming, magnet use under protocol, continuous monitoring, immediate access to external pacing and defibrillation, and interrogation before and after treatment.

A written plan should specify who is responsible for programming, observation, emergency response, and post-fraction checks. Australian radiotherapy centres commonly use structured protocols, including local eviQ-based practice, but individual device and treatment factors still require specialist review. The patient should carry an implant identification card and inform every oncology and hospital team about the device.

Extraction, Upgrade, And Complex Arrhythmia Care

Lead extraction is technically demanding in any patient and may be more complex after radiation because of fibrosis, venous occlusion, calcification, prior surgery, and poor tissue healing. Indications such as infection, lead malfunction, venous access requirements, or an upgrade to cardiac resynchronisation therapy should be weighed against procedural risk. If extraction is considered, referral to a high-volume centre with surgical backup, advanced imaging, blood-bank support, and an experienced extraction team is prudent.

Radiation-associated myocardial disease can create scar-mediated ventricular tachycardia, making an ICD necessary even after successful treatment of the original cancer. Epicardial or hybrid approaches may be relevant when endocardial substrate is inaccessible or previous procedures have failed; the discussion of epicardial VT ablation techniques provides useful context for procedural planning.

In Australia, complex cases are often referred to major electrophysiology centres in Sydney, Melbourne, Brisbane, Adelaide, or Perth. A referral should include radiotherapy records, imaging, device interrogation data, operative notes, anticoagulation details, and a clear statement of the clinical question. This helps reduce repeated testing and gives patients from rural and remote areas a more coordinated pathway.

Building A Long-Term Survivorship Plan

Device care should be integrated into cancer survivorship rather than treated as an isolated technical episode. The long-term plan may include blood pressure and lipid management, smoking cessation, exercise advice, surveillance for heart failure, assessment of valve disease, and prompt review of new exertional symptoms. Radiation exposure can interact with age, chemotherapy, diabetes, kidney disease, and inherited arrhythmic risk.

Patient education should use plain language. People need to know whether their device is a pacemaker, ICD, or resynchronisation system; when the next check is due; what to do after a shock; and which scans or procedures require device-team involvement. MRI access should be documented according to the exact system, since “MRI conditional” is a device-and-lead combination rather than a blanket label.

A coordinated record linking oncology, cardiology, electrophysiology, primary care, and the patient is especially valuable in Australia’s mixed public-private system. Device clinics should record the radiation history, pocket location, venous findings, extraction considerations, and future treatment constraints. This information can support safer care years after the original cancer treatment.

Clinicians managing survivors of thoracic or mediastinal radiotherapy should review the implant strategy, follow-up pathway, and emergency arrangements before the procedure is booked. Readers can explore the Journal of Arrhythmia’s clinical resources and related research to support evidence-informed decisions in complex device care, ablation, pacing, and arrhythmia management.